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MaOBJECTIVES The goal of this study was to compare survival between transcatheter mitral valve (MV) repair using
MitraClip system (Abbott Vascular, Santa Clara, California), MV-surgery, and conservative treatment in high-surgical-risk
patients symptomatic with severe mitral valve regurgitation (MR).
BACKGROUND Up to 50% of patients with symptomatic severe MR are denied for surgery due to high perioperative
risk. Transcatheter MV repair might be an alternative.
METHODS Consecutive patients (n ¼ 139) treated with transcatheter MV repair were included. Comparator surgically
(n ¼ 53) and conservatively (n ¼ 59) treated patients were identiﬁed retrospectively. Surgical risk was based on the
logistic European System for Cardiac Operative Risk Evaluation (log EuroSCORE) or the presence of relevant risk factors,
as judged by the heart team.
RESULTS The log EuroSCORE was higher in the transcatheter MV repair group (23.9  16.1%) than in the surgically
(14.2  8.9%) and conservatively (18.7  13.2%, p < 0.0001) treated patients. Left ventricular ejection fraction was
higher in surgical patients (43.9  14.4%, p ¼ 0.003), with similar values for the transcatheter MV repair (36.8  15.3%)
and conservatively treated (34.5  16.5%) groups. After 1 year of follow-up, the transcatheter MV repair and surgery
groups showed similar survival rates (85.8% and 85.2%, respectively), whereas 67.7% of conservatively treated patients
survived. The same trend was observed after the second and third years. After weighting for propensity score and
controlling for risk factors, both the transcatheter MV repair (hazard ratio [HR]: 0.41, 95% conﬁdence interval [CI]: 0.22
to 0.78, p ¼ 0.006) and surgical (HR: 0.52, 95% CI: 0.30 to 0.88, p ¼ 0.014) groups showed better survival than the
conservatively treated group. The transcatheter MV repair and surgical groups did not differ (HR: 1.25, 95% CI: 0.72 to
2.16, p ¼ 0.430).
CONCLUSIONS Despite a higher log EuroSCORE, high-surgical-risk patients with symptomatic severe MR treated with
transcatheter MV repair show similar survival rates compared with surgically treated patients, with both displaying
survival beneﬁt compared with conservative treatment. (J Am Coll Cardiol Intv 2014;7:875–81) © 2014 by the American
College of Cardiology Foundation.m the *Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; yDepartment of Cardiothoracic Surgery,
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CI = conﬁdence interval
log EuroSCORE = logistic
European System for Cardiac
Operative Risk Evaluation
FMR = functional mitral valve
regurgitation
HR = hazard ratio
LV = left ventricular
LVEF = left ventricular ejection
fraction
MR = mitral regurgitation
MV = mitral valve
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876M itral valve (MV) regurgitation(MR) is an important clinical con-dition, representing >30% of
native valve diseases (1). In the absence of
surgery, patients with symptomatic MR have
a poor prognosis, even with optimal medical
therapy (2). Indeed, it has been shown that
medical therapy does not reduce survival
and only improves symptoms of heart failure
(3). Therefore, the guidelines recommend sur-
gical treatment with a class I (4,5). Despite this
clear statement, Euro Heart Survey on valve
disease indicates that up to 50% of these
patients are not referred for surgery due to
high peri- and postoperative risk, mainly
driven by advanced age, depressed left ven-
tricular (LV) function, and other comorbid-ities (6). Higher percentages of rejections have been
reported recently, when MR was accompanied by
heart failure (7). The reported in-hospital mortality
rate in these high-surgical-risk patients is estimatedSEE PAGE 882to be up to 25% (8,9). New transcatheter techniques
may introduce an alternative to surgery in high-
surgical-risk patients. In the past few years, most evi-
dence on transcatheter MV repair has accumulated for
transcatheter edge-to-edge MV repair using the
MitraClip system (Abbott Vascular, Santa Clara, Cali-
fornia) (10–16). Mimicking the surgical procedure
introduced by Alﬁeri et al. (17), this technique creates
a double MV oriﬁce by means of a clip in the midpor-
tion of the 2 leaﬂets. Previous studies, also from our
group, proved the MitraClip system’s feasibility and
efﬁcacy in high-surgical-risk patients (10,13–16). No
data are available comparing outcomes of transcath-
eter MV repair with surgery and conservative treat-
ment in high-surgical-risk patients. In this study,
we aimed to compare survival outcomes in these
different treatment strategies in high-surgical-risk
patients with symptomatic MR.METHODS
PATIENTS. All consecutive patients between January
2009 and April 2013 who underwent transcatheter MV
repair, were included. The suitability was determined
by the heart team, consisting of cardiac surgeons and
interventional, imaging and heart failure cardiolo-
gists at our hospital. The patients undergoing trans-
catheter MV repair therapy were at high-surgical-risk
based on the logistic European System for Cardiac
Operative Risk Evaluation (log EuroSCORE) (18) of atleast 20% or were denied for surgery due to a com-
bination of additional factors associated with an
increase in mortality judged by the heart team, con-
sisting of an LV ejection fraction (LVEF) <30%, older
than 80 years of age, previous cardiac surgery, body
mass index >35 or <18 kg/m2, pulmonary hyperten-
sion, renal insufﬁciency, previous chest radiation,
chronic obstructive pulmonary disease and emphy-
sema, porcelain aorta, and frailty.
We retrospectively analyzed all patients who were
discussed by the heart team 2 years before the start
date of transcatheter MV repair, during a period when
this therapy was not available in our hospital. The
therapeutic strategy was reviewed in all patients
referred for MV surgery because of symptomatic
severe MR. Accepted high-risk surgery patients and
patients who were denied surgery (conservatively
treated group), who today might be considered for
transcatheter MV repair, were considered as control
groups. All patients had moderate to severe or severe
MR (grade 3þ or 4þ) and were symptomatic with or
without LV dysfunction (ejection fraction <60%) or
LV dilation (LV end-systolic diameter >45 mm) and
consequently had an indication for intervention ac-
cording to the European Society of Cardiology Task
Force recommendation (5). High surgical risk was
based on log EuroSCORE or the presence of relevant
risk factors associated with excessive morbidity
and mortality as judged by the heart team. These
factors included the same factors considered for risk
assessment of transcatheter MV repair patients as
mentioned earlier. In the high-risk surgery group,
concomitant coronary artery bypass grafting (CABG)
was allowed if these lesions could also be treated with
a percutaneous intervention. Patients with concomi-
tant aortic valve pathology were excluded.
Individual patient charts were evaluated for clin-
ical characteristics, including patient demographic
characteristics, risk factors, and operative data.
Follow-up survival information was evaluated by
consulting the government death registries by the
Social Security number.
All patients included in the study were fully
informed about the procedure and signed a written
consent form. The study was approved by the hospi-
tal’s ethics committee (W13.024 and R&D/Z-13.15).
The procedures were performed in accordance with
the hospital’s ethics standards and the 1975 Declara-
tion of Helsinki (revised in 2008).
PROCEDURE. All procedures were performed as pre-
viously described (14,19,20). In brief, the clip device
system is delivered to the left atrium via a transseptal
puncture, advanced into the left ventricle, and then
TABLE 1 Baseline Characteristics
Characteristic MitraClip
High-Risk
Surgery
Conservative
Treatment p Value
No. 139 53 59
Age, yrs 74.6  9.4 70.2  9.5 71.7  9.6 0.009
Male, % 94 (67.6) 27 (50.9) 32 (54.2) 0.051
BMI, kg/m2 25.9  4.7 26.7  5.3 26.5  4.5 0.53
LVEF, % 36.8  15.3 43.9  14.4 34.5  16.5 0.003
Log EuroSCORE, % 23.9  16.0 14.2  8.9 18.7  13.2 <0.0001
Comorbidities
Hypertension 74 (53.2) 28 (52.8) 25 (42.4) 0.35
Diabetes mellitus 32 (23) 10 (18.9) 17 (28.8) 0.46
Atrial ﬁbrillation 74 (53.2) 27 (50.9) 24 (40.7) 0.27
COPD 31 (22.3) 15 (28.3) 19 (32.2) 0.31
Known CAD 89 (64.0) 28 (52.8) 45 (76.3) 0.03
Previous MI 72 (51.1) 13 (24.5) 25 (42.4) 0.004
History of PCI 41 (29.5) 5 (9.4) 9 (15.3) 0.002
History of CABG 59 (42.4) 9 (17.0) 11 (18.6) <0.0001
History of CRT 30 (21.6) 1 (1.9) 2 (3.4) <0.0001
Renal insufﬁciency* 55 (39.6) 9 (17.0) 18 (30.5) 0.01
Pulmonary hypertension† 0.005
No 15 (10.8) 11 (20.8) 14 (23.7)
Moderate 99 (71.2) 28 (52.8) 26 (44.1)
Severe 25 (18.0) 14 (26.4) 19 (32.2)
NYHA functional class 0.74
II 16 (11.5) 6 (11.3) 8 (13.6)
III 91 (65.5) 38 (71.7) 35 (59.3)
IV 32 (23.0) 9 (17.0) 16 (27.1)
Etiology 0.005
FMR 107 (77.0) 31 (58.5) 48 (81.3)
DMR 25 (18.0) 17 (32.1) 4 (6.8)
Mixed 7 (5.0) 5 (9.4) 7 (11.9)
Values are mean  SD or number (%). *Glomerular ﬁltration rate <45 ml/min/1.73 m2. †Moderate pulmonary
hypertension was deﬁned as systolic pulmonary artery pressure 31 to 55 mm Hg; severe was deﬁned as systolic
pulmonary artery pressure >55 mm Hg.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; COPD ¼
chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; DMR ¼ degenerative mitral
valve regurgitation; FMR ¼ functional mitral valve regurgitation; log EuroSCORE ¼ logistic European System for
Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼
New York Heart Association; PCI ¼ percutaneous coronary intervention.
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877retracted during systole, grasping the MV leaﬂets.
This results in permanent leaﬂet approximation and
creation of a double oriﬁce. The clip is a 4-mm-wide
cobalt-chromium implant with 2 arms. On the inner
portion of the clip arms are small “grippers” to secure
the leaﬂets when the arms are closed. To position the
clip device correctly over the mitral oriﬁce, it should
be placed perpendicular to the line of leaﬂet coapta-
tion and above the origin of the MR jet. These factors
are mandatory to prevent clip disengagement and to
obtain an acceptable MR reduction. A second (or
third) clip was placed if further reduction of MR was
required. The procedure was performed with patients
under general anesthesia and both ﬂuoroscopic and
transesophageal echocardiographic (2- and 3-
dimensional) guidance (19,20).
The surgical techniques used by the surgeon have
been described previously and are considered as
standard surgical therapy (21–23). The particular
choice of technique was entirely at the discretion of
the individual surgeon.
STATISTICAL ANALYSIS. Data are given as mean SD
in the text and in Table 1. The dichotomous variables
were tested by the chi-square test. Comparisons be-
tween groups were done by analysis of variance, with
the least signiﬁcant difference test as a post-hoc test.
To reduce confounding factors due to imbalances
in baseline characteristics, propensity scores were
used to weight samples from the transcatheter MV
repair, surgery, and control groups so that the dis-
tributions of observed baseline characteristics were
more comparable across the 3 groups. We computed
propensity scores by means of generalized boosted
modeling, a machine learning technique that relies on
tree-based regression models that are built in an
iterative fashion with a multinomial approach trying
to achieve balance among the 3 groups (24). We used
log EuroSCORE, age, chronic obstructive pulmonary
disease, known coronary artery disease (CAD), pre-
vious myocardial infarction, history of CABG, history
of percutaneous coronary intervention, glomerular
ﬁltration rate <45 ml/min/1.73 m2, pulmonary hy-
pertension, LVEF, cardiac resynchronization therapy
in situ, and etiology of MR as potential confounders
plus 20,000 iterations for the estimation of the pro-
pensity scores. Subsequently, the propensity scores
were used for inverse probability of treatment
weighting in a Cox proportional hazards model after
survey sampling methodology. Finally, we estimated
the treatment effects (hazard ratio [HR]) doubly
robust through weighted regression on the treatment
indicators as well as adding covariates that were still
statistically different between the 3 treatment groupsand/or were known confounders from previous
studies (cardiac resynchronization therapy and log
EuroSCORE). We used the procedures implemented
in the twang package for R (twang: Toolkit for
Weighting and Analysis of Nonequivalent Groups; R
package version 1.3-18 (R Package for Statistical
Computing, Vienna, Austria).
For statistical analysis, SPSS version 21.0 (SPSS
Inc., Chicago, Illinois) and R version 2.15 (R Package
for Statistical Computing, Vienna, Austria) were used.
p Values <0.05 (2 tailed) were considered statistically
signiﬁcant.
RESULTS
BASELINE CHARACTERISTICS. Transcatheter MV
repair was carried out in 139 patients (mean age,
FIGURE 1 Kaplan-Meier Survival Curves
After 1-year follow-up, the transcatheter mitral valve (MV) repair and the high-risk surgery group had similar survival rates (85.8% vs. 85.2%,
respectively), whereas only 67.7% of the patients in the conservatively treated group survived. The same trend was observed during the second
and third year of follow-up.
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87874.6  9.4 years; 67.6% male). In 2007 and 2008,
a total 307 patients underwent surgical procedures
consisting of MV repair or replacement with or
without CABG. Of these, 53 patients (mean age, 70.2 
9.5 years; 50.9% male) were considered as high risk.
The patients undergoing concomitant CABG (n ¼ 12)
had coronary lesions (>50% stenosis), which also
could be treated with a percutaneous intervention.
Surgical MV repair was carried out in 38 patients. Ten
and 5 patients underwent MV replacement with a
bioprosthesis and mechanoprosthesis, respectively.
Fifty-nine patients (mean age, 71.7  9.6 years;
54.2% male) were treated conservatively.
Mean follow-up time was 1.7  1.1, 3.8  1.9, and 2.7
 2.2 years for the transcatheter MV repair, high-risk
surgery and conservatively treated groups, respec-
tively. Table 1 shows the baseline characteristics of the
different groups. There were signiﬁcantly more male
patients in the transcatheter MV repair group com-
pared with the other groups. No difference in sex was
found between high-risk surgery and conservatively
treated patients. Log EuroSCORE was signiﬁcantlyhigher in the transcatheter MV repair group than in the
other groups. No difference was found for this score
between high-risk surgery and conservatively treated
patients.
The majority of the patients in all groups had
functional MR. Compared with the other groups, the
high-risk surgery group displayed relatively more
patients with degenerative MR.
The prevalence of known CAD was highest in the
conservatively treated group (76.3%) and the lowest
in the high-risk surgery patients (52.8%). However,
when a history of coronary ischemic events (previous
myocardial infarction) and treatment (percutaneous
coronary intervention and CABG) were considered,
the highest frequencies were observed in the trans-
catheter MV repair group.
In total, pulmonary hypertension was more
prevalent in the transcatheter MV repair group, but
severe pulmonary hypertension (systolic pulmonary
artery pressure >55 mm Hg) was more common in
the high-risk surgery and conservatively treated
group.
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879LVEF was signiﬁcantly higher in the high-risk sur-
gery group, showing similar values for the trans-
catheter MV repair and conservatively treated
patients.
Acute procedural success (MR #2þ) was achieved
in 127 patients (93.4%) in the transcatheter MV repair
group.
SURVIVAL OUTCOMES. After 1 year of follow-up, the
transcatheter MV repair and the high-risk surgery
group showed similar survival rates (85.8% vs. 85.2%,
respectively), whereas only 67.7% of the patients in
the conservatively treated group survived (Fig. 1). The
2- and 3-year survival rates in the conservatively
treated group were 52.5% and 45.8%, respectively.
The survival rates for the transcatheter MV repair
group (75.5% and 62.3% after 2 and 3 years, respec-
tively) and high-risk surgery group (77.8% and 68.5%
after 2 and 3 years, respectively) were comparable.
During follow-up, there were 29 cardiac deaths and
6 noncardiac deaths in the transcatheter MV repair
group. In the high-risk surgery group, 18 cardiac
deaths and 5 noncardiac deaths were reported.
Finally, 39 cardiac deaths and 3 noncardiac deaths
occurred in the conservatively treated group.
After weighting for propensity score and control-
ling for cardiac resynchronization therapy and log
EuroSCORE, both treatment groups showed superior
survival rates compared with the conservatively
treated group: transcatheter MV repair versus con-
servative treatment (HR: 0.41, 95% CI: 0.22 to 0.78,
p ¼ 0.006) and surgical treatment versus conservative
treatment (HR: 0.52, 95% CI: 0.30 to 0.88, p ¼ 0.014).
Both treatment groups did not differ statistically
signiﬁcantly: surgical treatment versus transcatheter
MV repair (HR: 1.25, 95% CI: 0.72 to 2.16, p ¼ 0.43).
Whether sufﬁcient baseline comparability was
achieved with the propensity-weighting analysis is
difﬁcult to prove. We therefore undertook an addi-
tional analysis by means of propensity matching,
keeping only triplets (1 from each treatment modal-
ity) of patients who were comparable within 0.25 SE.
Eighty-one matching triplets could be used in a con-
ditional Cox proportional hazards model, resulting in
a comparable outcome, but with broader conﬁdence
intervals. The MitraClip versus conservative treat-
ment comparison was still statistically signiﬁcant
(HR: 0.47, 95% CI: 0.24 to 0.93).
If only patients with functional MR (FMR) were
considered, the same trend was observed as described
above; transcatheter MV repair versus conservative
treatment (HR: 0.46, 95% CI: 0.23 to 0.93, p ¼ 0.03)
and surgical treatment versus conservative treatment
(HR: 0.54, 95% CI: 0.29 to 1.02, p ¼ 0.057). Bothtreatment groups did not differ statistically signiﬁ-
cantly: surgical treatment versus transcatheter MV
repair (HR: 0.84. 95% CI: 0.45 to 1.59, p ¼ 0.60).
DISCUSSION
This is the ﬁrst study to compare transcatheter MV
repair with surgical and conservative treatment in
high-surgical-risk patients with symptomatic MR. We
show that this relatively new transcatheter technique
is superior to conservative treatment and that the
survival rates after transcatheter MV repair are com-
parable to classic surgery, despite a higher log
EuroSCORE.
Agricola et al. (2) reported that conservative treat-
ment of symptomatic moderate to severe MR is
associated with a 50% risk of mortality at 4-year
follow-up. Similar mortality rates were reported
recently by Goel et al. (7) after 5 years of follow-up.
The baseline characteristics of the patients enrolled
in that study resemble those of our MV repair study
group in terms of LV dysfunction, age, and other
comorbidities. In our study, the mortality rate of
conservatively treated patients was even higher with
54.2% mortality after 3 years. Therefore, trans-
catheter MV repair with a survival rate of 62.3%
after 3 years could be the preferred treatment in high-
surgical-risk patients and/or patients denied surgery.
These ﬁndings are comparable with the high-risk
registry data from the EVEREST II (Endovascular
Valve Edge-to-Edge Repair) trial showing superior
survival rates with transcatheter MV repair compared
with conservative treatment (16).
The “standard” treatment of MR is surgery. Logi-
cally, the patients denied for surgery must be at
increased surgical risk. Indeed, it has been suggested
that the patient risk factors differ signiﬁcantly
between surgical patients and transcatheter MV
repair patients, favoring surgical patients (25). In an
era in which up to 50% of patients are denied surgery,
simply because of that high risk, transcatheter MV
repair would be the only alternative therapy! The
landmark EVEREST II trial, in which patients at low
and moderate risk were also included, showed that
the survival rates were similar between transcatheter
MV repair and surgery groups (12,26). Our report
expands the EVEREST II data on high-surgical-risk
patients, suggesting that transcatheter MV repair
may even be as good as surgical therapy. Further
improvement of the survival rates may be expected
by gaining experience leading to improved durability
and completeness of MV repair (27).
Finally, there is controversy in the literature con-
cerning surgical treatment of FMR in terms of survival
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880beneﬁts. In fact, it has been suggested that surgical
treatment is not better than conservative therapy in
high-surgical-risk patients with FMR (28). In our
cohort, 77% of the transcatheter MV repair patients
and 81% of the conservatively treated group had
FMR. Despite this high percentage and high periop-
erative risk, the transcatheter MV repair group
showed superior survival gain compared with con-
servative therapy. Patients with FMR may even
beneﬁt the most from transcatheter MV repair, as has
been suggested by others (10,13,29). Indeed, the Eu-
ropean Guidelines recommend transcatheter MV
repair, if feasible at low procedure risk, to treat pa-
tients with FMR without severe tethering to provide
short-term improvement in functional class and LV
function (5). In our study, if only patients with FMR
were considered, the same trend was observed as
described for the total group. To further investigate
the hypothesis that transcatheter MV repair has
superior survival beneﬁts over conservative therapy
in high-surgical-risk patients with FMR, 2 randomized
clinical trials have been designed to compare trans-
catheter MV repair in addition to optimal standard
medical therapy with optimal standard of care ther-
apy alone: the COAPT (Clinical Outcomes Assessment
of the MitraClip Percutaneous Therapy for High
Surgical Risk Patients) trial and the RESHAPE-HF
(Randomized Study of the MitraClip Device in Heart
Failure Patients With Clinically Signiﬁcant Functional
Mitral Regurgitation), both in the recruitment phase.STUDY LIMITATIONS. These include the non-
randomized character and the fact that the comparator
groups were recruited retrospectively. Despite its
retrospective and nonrandomized character, we
believe that our study advocates enough potential for
transcatheter MV repair to be a good alternative to
high-risk surgery and a serious treatment option for
patients denied surgery. Another limitation is that we
did not describe secondary endpoints such as residual
MR grade, signs of reverse LV remodeling, NYHA
functional classiﬁcation, and rehospitalization. Our
only objective was to investigate the primary endpoint
of mortality in the 3 different treatment strategies, and
the investigation of secondary endpoints was beyond
the scope of our study. The upcoming randomized
clinical trials will provide data on these topics.
CONCLUSIONS
Despite higher log EuroSCORE, high-surgical-risk pa-
tients with severe symptomatic MR treated with the
transcatheter MV repair show similar survival rates
compared with those undergoing surgery, with both
showing survival beneﬁt compared with conservative
treatment.
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